Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation

Ellie Coromilas, Em Claire Que-Xu, D'Vesharronne V. Moore, Tomoko S. Kato, Christina Wu, Ruiping Ji, Raymond Givens, Ulrich P. Jorde, Hiroo Takayama, Yoshifumi Naka, Isaac George, Donna Mancini, P. Christian Schulze

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a prognostic indicator. Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF (n = 55), severe HF (n = 63), at 3 (n = 17) and 6 (n = 14) months post-LVAD and at LVAD explantation (n = 23), patients following HTx (n = 85) and healthy controls (n = 30). Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001; controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower (3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation (40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD placement (76.5 % versus 95.0 % at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1ng/ml post-HTx versus 28.2 ± 14 pre-HTx; p <0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher galectin-3 levels (20.5 ± 8.8ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3 (r 2 = 0.17, p <0.0001). Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3 might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.

Original languageEnglish (US)
Article number138
JournalBMC Cardiovascular Disorders
Volume16
Issue number1
DOIs
StatePublished - Jun 14 2016
Externally publishedYes

Fingerprint

Galectin 3
Heart-Assist Devices
Heart Transplantation
Heart Failure
Allografts
Survival

Keywords

  • Coronary Allograft Vasculopathy
  • Galectin-3
  • Heart Failure
  • Heart Transplantation
  • LVAD

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. / Coromilas, Ellie; Que-Xu, Em Claire; Moore, D'Vesharronne V.; Kato, Tomoko S.; Wu, Christina; Ji, Ruiping; Givens, Raymond; Jorde, Ulrich P.; Takayama, Hiroo; Naka, Yoshifumi; George, Isaac; Mancini, Donna; Schulze, P. Christian.

In: BMC Cardiovascular Disorders, Vol. 16, No. 1, 138, 14.06.2016.

Research output: Contribution to journalArticle

Coromilas, E, Que-Xu, EC, Moore, DVV, Kato, TS, Wu, C, Ji, R, Givens, R, Jorde, UP, Takayama, H, Naka, Y, George, I, Mancini, D & Schulze, PC 2016, 'Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation', BMC Cardiovascular Disorders, vol. 16, no. 1, 138. https://doi.org/10.1186/s12872-016-0298-z
Coromilas, Ellie ; Que-Xu, Em Claire ; Moore, D'Vesharronne V. ; Kato, Tomoko S. ; Wu, Christina ; Ji, Ruiping ; Givens, Raymond ; Jorde, Ulrich P. ; Takayama, Hiroo ; Naka, Yoshifumi ; George, Isaac ; Mancini, Donna ; Schulze, P. Christian. / Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. In: BMC Cardiovascular Disorders. 2016 ; Vol. 16, No. 1.
@article{a450db0d89224a0b941f120310a41b07,
title = "Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation",
abstract = "Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a prognostic indicator. Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF (n = 55), severe HF (n = 63), at 3 (n = 17) and 6 (n = 14) months post-LVAD and at LVAD explantation (n = 23), patients following HTx (n = 85) and healthy controls (n = 30). Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001; controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower (3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation (40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD placement (76.5 {\%} versus 95.0 {\%} at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1ng/ml post-HTx versus 28.2 ± 14 pre-HTx; p <0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher galectin-3 levels (20.5 ± 8.8ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3 (r 2 = 0.17, p <0.0001). Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3 might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.",
keywords = "Coronary Allograft Vasculopathy, Galectin-3, Heart Failure, Heart Transplantation, LVAD",
author = "Ellie Coromilas and Que-Xu, {Em Claire} and Moore, {D'Vesharronne V.} and Kato, {Tomoko S.} and Christina Wu and Ruiping Ji and Raymond Givens and Jorde, {Ulrich P.} and Hiroo Takayama and Yoshifumi Naka and Isaac George and Donna Mancini and Schulze, {P. Christian}",
year = "2016",
month = "6",
day = "14",
doi = "10.1186/s12872-016-0298-z",
language = "English (US)",
volume = "16",
journal = "BMC Cardiovascular Disorders",
issn = "1471-2261",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation

AU - Coromilas, Ellie

AU - Que-Xu, Em Claire

AU - Moore, D'Vesharronne V.

AU - Kato, Tomoko S.

AU - Wu, Christina

AU - Ji, Ruiping

AU - Givens, Raymond

AU - Jorde, Ulrich P.

AU - Takayama, Hiroo

AU - Naka, Yoshifumi

AU - George, Isaac

AU - Mancini, Donna

AU - Schulze, P. Christian

PY - 2016/6/14

Y1 - 2016/6/14

N2 - Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a prognostic indicator. Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF (n = 55), severe HF (n = 63), at 3 (n = 17) and 6 (n = 14) months post-LVAD and at LVAD explantation (n = 23), patients following HTx (n = 85) and healthy controls (n = 30). Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001; controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower (3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation (40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD placement (76.5 % versus 95.0 % at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1ng/ml post-HTx versus 28.2 ± 14 pre-HTx; p <0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher galectin-3 levels (20.5 ± 8.8ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3 (r 2 = 0.17, p <0.0001). Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3 might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.

AB - Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a prognostic indicator. Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF (n = 55), severe HF (n = 63), at 3 (n = 17) and 6 (n = 14) months post-LVAD and at LVAD explantation (n = 23), patients following HTx (n = 85) and healthy controls (n = 30). Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001; controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower (3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation (40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD placement (76.5 % versus 95.0 % at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1ng/ml post-HTx versus 28.2 ± 14 pre-HTx; p <0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher galectin-3 levels (20.5 ± 8.8ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3 (r 2 = 0.17, p <0.0001). Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3 might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.

KW - Coronary Allograft Vasculopathy

KW - Galectin-3

KW - Heart Failure

KW - Heart Transplantation

KW - LVAD

UR - http://www.scopus.com/inward/record.url?scp=84973650071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973650071&partnerID=8YFLogxK

U2 - 10.1186/s12872-016-0298-z

DO - 10.1186/s12872-016-0298-z

M3 - Article

VL - 16

JO - BMC Cardiovascular Disorders

JF - BMC Cardiovascular Disorders

SN - 1471-2261

IS - 1

M1 - 138

ER -